Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® ProgramPRNewsWire • 09/09/21
BofA Downgrades Alkermes After Stock Rally: 'We Don't See A Favorable Catalyst Pathway'Benzinga • 09/02/21
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal MelanomaPRNewsWire • 08/02/21
Alkermes Plc (ALKS) CEO Richard Pops on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/28/21
Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol DependencePRNewsWire • 06/30/21
Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness CampaignPRNewsWire • 06/22/21
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating BreakthroughsThe Motley Fool • 06/13/21
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual MeetingPRNewsWire • 06/04/21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I DisorderPRNewsWire • 06/01/21
Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 05/28/21